The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
The company recently launched Prompt Prostate Genetic Score, a lab-developed test to track a man's genetic predisposition to prostate cancer.
The French company develops software solutions for digital pathology, including software for microscopic and macroscopic image management.
The financing will go toward ongoing commercialization of the firm's autoimmune tests and therapeutics promotion business.
The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.
The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.
The German firm, spun off from a marine research institute, recently closed a €1 million seed financing round to support expansion of the company and drive adoption.
One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to develop a point-of-care diagnostic platform for infectious disease.
Seventh Sense Biosystems markets a one-step, push-button device called Tap that uses a microneedle array to collect capillary blood from the arm.
The firm is developing a portable, rapid MDx platform for infectious disease testing in clinics, and anticipates launching a first product in 2020.